Skip to main content
SpringerLink
Log in

Zollinger-Ellison syndrome

  • Chapter
Proton Pump Inhibitors

Part of the book series: Milestones in Drug Therapy MDT ((MDT))

Abstract

The discovery of omeprazole and the subsequent development of other proton pump inhibitors (lansoprazole, pantoprazole) has had a profound effect on the management of Zollinger-Ellison syndrome (ZES) as well as other gastric hypersecretory states.These drugs have now become the drugs of choice for these conditions [1]. The focus of this chapter will be their impact on Zollinger-Ellison syndrome, because of all the gastric hypersecretory states this disease demonstrates the most profound gastric acid hypersecretion and has been the best studied. Although there are a few studies with lansoprazole and pantoprazole (Tab. 1), most of the detailed studies (Tab. 1) [2–13] have been performed using omeprazole, so these studies will be primarily emphasized in this chapter. To understand the impact of omeprazole on the treatment of ZES, it is essential to understand the treatment regimens that existed prior to its introduction in the early 1980s for treatment of ZES [2, 3, 14].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Jensen RT (1996) Gastrinoma. Clin Gastroenterol 10: 555–766

    Google Scholar 

  2. Lamers CBHW, Lind T, Moberg S, Jansen JBMJ, Olbe L (1984) Omeprazole in Zollinger-Ellison syndrome: effects of a single dose and of long term treatment in patients resistant to histamine H2-receptor antagonists. N Engl J Med 310: 758–761

    Article  Google Scholar 

  3. McArthur KE, Collen MJ, Maton PN, Cherner JA, Howard JM, Ciarleglio CA, Cornelius MJ, Jensen RT, Gardner JD (1985) Omeprazole: effective, convenient therapy for Zollinger-Ellison syndrome. Gastroenterology 88: 939–944

    PubMed  CAS  Google Scholar 

  4. Delchier JC, Soule JC, Mignon M, Goldfain D, Cortot A, Travers B, Isal JP, Bader JP (1986) Effectiveness of omeprazole in seven patients with Zollinger-Ellison syndrome resistant to histamine H2-receptor antagonists. Dig Dis Sci 31: 693–699

    Article  PubMed  CAS  Google Scholar 

  5. Bardram L, Stadil F (1986) Omeprazole in the Zollinger-Ellison syndrome. Scand J Gastroenterol 21: 374–378

    Article  PubMed  CAS  Google Scholar 

  6. Lloyd-Davies ICA, Rutgersson K, Solvell L (1988) Omeprazole in the treatment of Zollinger-Ellison syndrome: a 4-year international study. Aliment Pharmacol Ther 2: 13–32

    Article  PubMed  CAS  Google Scholar 

  7. Hirschowitz BI, Denen J, Raufman J, LaMont B, Berman R, Humphries T (1988) A multicenter US study of omeprazole treatment of Zollinger-Ellison syndrome. Gastroenterology 94: A188 (abstract)

    Google Scholar 

  8. Maton PN, Vinayek R, Frucht H, McArthur KA, Miller LS, Saeed ZA, Gardner JD, Jensen RT (1989) Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Gastroenterology 91: 827–836

    Google Scholar 

  9. Lehy T, Mignon M, Cadiot G, Elouaer-Blanc L, Ruszniewski P, Lewin MJ, Bonfils S (1989) Gastric endocrine cell behavior in Zollinger-Ellison patients upon long-term potent antisecretory treatment. Gastroenterology 96: 1029–1040

    PubMed  CAS  Google Scholar 

  10. Metz DC, Strader DB, Orbuch M, Koviach PD, Feigenbaum KM, Jensen RT (1993) Use of omeprazole in Zollinger-Ellison: a prospective nine-year study of efficacy and safety. Aliment Pharmacol Ther 7: 597–610

    Article  PubMed  CAS  Google Scholar 

  11. Corleto V, Annibale B, D’Ambra G, Saggioro A, Ferrua B, Cassetta MR, Delia Fave G (1993) Efficacy of long-term therapy with low doses of omeprazole in the control of gastric acid secretion in Zollinger-Ellison syndrome patients. Aliment Pharmacol Ther 7: 167–173

    Article  PubMed  CAS  Google Scholar 

  12. Metz DC, Jensen RT (1995) Advances in gastric antisecretory therapy in Zollinger-Ellison syndrome. In: M Mignon, RT Jensen (eds): Endocrine tumors of the pancreas: recent advances in research and management. Series: Frontiers of Gastrointestinal Research. S. Karger, Basel, Switzerland, 240–257

    Google Scholar 

  13. Metz DC, Pisegna JR, Fishbeyn VA, Benya RV, Feigenbaum KM, Koviack PD, Jensen RT (1992) Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology 103: 1498–1508

    PubMed  CAS  Google Scholar 

  14. Jensen RT, Gardner JD (1993) Gastrinoma. In: VLW Go, EP DiMagno, JD Gardner, E Lebenthal, HA Reber, G A Scheele (eds): The pancreas: biology, pathobiology and disease. Raven Press, New York, 931–978

    Google Scholar 

  15. Stadil F, Stage JG (1978) Cimetidine and the Zollinger-Ellison (Z-E) syndrome. In: C Wastell, P Lance (eds): Cimetidine, The Westminster Hospital Symposium. London: Churchill Livingstone, 91–104

    Google Scholar 

  16. Bonfils S, Mignon M, Gratton J (1979) Cimetidine treatment of acute and chronic Zollinger-Ellison syndrome. World J Surg 3: 597–604

    Article  PubMed  CAS  Google Scholar 

  17. Collen MJ, Howard JM, McArthur KE, Raufman JP, Cornelius MJ, Ciarleglio CA, Gardner JD, Jensen RT (1984) Comparison of ranitidine and cimetidine in the treatment of gastric hypersecretion. Ann Intern Med 100: 52–58

    PubMed  CAS  Google Scholar 

  18. Deveney CW, Stein S, Way LW (1983) Cimetidine in the treatment of Zollinger-Ellison syndrome. Am J Surg 146: 116–123

    Article  PubMed  CAS  Google Scholar 

  19. Jensen RT, Gardner JD, Raufman JP, Pandol SJ, Doppman JL, Collen MJ (1983) Zollinger-Ellison syndrome: current concepts and management. Ann Intern Med 98: 59–75

    PubMed  CAS  Google Scholar 

  20. McCarthy DM (1978) Report on the United States experience with cimetidine in Zollinger-Ellison syndrome and other hypersecretory states. Gastroenterology 74: 453–458

    PubMed  CAS  Google Scholar 

  21. Stabile BE, Ippoliti AF, Walsh JH, Passaro E Jr (1983) Failure of histamine H2-receptor antagonist therapy in Zollinger-Ellison syndrome. Am J Surg 84(6): 1621–1623

    Google Scholar 

  22. Malagelada J, Edis AJ, Adson MA, Van Heerden JA, Go VLW (1983) Medical and surgical options in the management of patients with gastrinoma. Gastroenterology 84: 1524–1532

    PubMed  CAS  Google Scholar 

  23. Vinayek R, Howard JM, Maton PN, Wank SA, Slaff JI, Gardner JD, Jensen RT (1986) Famotidine in the therapy of gastric hypersecretory states. Am J Med 81: 49–59

    Article  PubMed  CAS  Google Scholar 

  24. Mignon M, Vallot T, Hervoir P, Benfredo P, Bonfils S (1982) Ranitidine versus Cimetidine in the management of Zollinger-Ellison syndrome. In: AJ Riley, PR Salmon (eds): Ranitidine, Proceedings of an International Symposium, World Congress of Gastroenterology, Stockholm, Excerpta Medica, Amsterdam, 169–177

    Google Scholar 

  25. Vezzadini P, Bonora G, Tomassetti P, Pazzaglia M, Labo G (1983) Medical treatment of Zollinger-Ellison syndrome with ranitidine. Int J Tiss Reac 4: 339–343

    Google Scholar 

  26. Howard JM, Chremos AN, Collen MJ, McArthur KE, Cherner JA, Maton PN, Ciarleglio CA, Cornelius MJ, Gardner JD, Jensen RT (1985) Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome. Gastroenterology 88: 1026–1033

    PubMed  CAS  Google Scholar 

  27. Jensen RT (1984) Basis for failure of cimetidine in patients with Zollinger-Ellison syndrome. Dig Dis Sci 29: 363–366

    Article  PubMed  CAS  Google Scholar 

  28. Raufman JP, Collins SM, Pandol SJ, Korman LY, Collen MJ, Cornelius MJ, Feld MK, McCarthy DM, Gardner JD, Jensen RT (1983) Reliability of symptoms in assessing control of gastric acid secretion in patients with Zollinger-Ellison syndrome. Gastroenterology 84: 108–113

    PubMed  CAS  Google Scholar 

  29. Maton PN, Frucht H, Vinayek R, Wank SA, Gardner JD, Jensen RT (1988) Medical management of patients with Zollinger-Ellison syndrome who have had previous gastric surgery: a prospective study. Gastroenterology 94: 294–299

    PubMed  CAS  Google Scholar 

  30. Miller LS, Vinayek R, Frucht H, Gardner JD, Jensen RT, Maton PN (1990) Reflux esophagitis in patients with Zollinger-Ellison syndrome. Gastroenterology 98: 341–346

    Article  PubMed  CAS  Google Scholar 

  31. Jensen RT, Collen MJ, Allende HD, Pandol SJ, Raufman JP, Bissonnette BM, Duncan WC, Durgin PL, Gillin JC, Gardner JD (1983) Cimetidine-induced impotence and breast changes in patients with gastric hypersecretory states. N Engl J Med 308: 883–887

    Article  PubMed  CAS  Google Scholar 

  32. Vinayek R, Amantea MA, Maton PN, Frucht H, Gardner JD, Jensen RT (1991) Pharmacokinetics of oral and intravenous omeprazole in patients with the Zollinger-Ellison syndrome. Gastroenterology 101: 138–147

    PubMed  CAS  Google Scholar 

  33. Metz DC, Pisegna JR, Ringham GL, Feigenbaum KM, Koviack PD, Maton PN, Gardner JD, Jensen RT (1993) Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome. Dig Dis Sci 38: 245–256

    Article  PubMed  CAS  Google Scholar 

  34. Termanini B, Gibril F, Stewart CA, Weber HC, Jensen RT (1996) A prospective study of the effectiveness of low dose omeprazole as initial therapy in Zollinger-Ellison syndrome. Aliment Pharmacol Ther 10: 61–71

    Article  PubMed  CAS  Google Scholar 

  35. Metz DC, Pisegna JR, Fishbeyn VA, Benya RV, Jensen RT (1993) Control of gastric acid hypersecretion in the management of patients with Zollinger-Ellison syndrome. World J Surg 17: 468–480

    Article  PubMed  CAS  Google Scholar 

  36. Jensen RT, Metz DC, Koviack PD, Feigenbaum KM (1993) Prospective study of the long-term efficacy and safety of lansoprazole in patients with Zollinger-Ellison syndrome. Aliment Pharmacol Ther 1 (Suppl 1): 41–50

    Google Scholar 

  37. Mignon M, Pospai D, Forestier S, Vatier J, Vallot T (1993) Treatment of patients with Zollinger-Ellison syndrome. Clin Ther 15: 22–31

    PubMed  Google Scholar 

  38. Hirschowitz BI, Mohnen J, Shaw S (1996) Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome. Aliment Pharmacol Ther 10: 507–522

    Article  PubMed  CAS  Google Scholar 

  39. Radebold K, Bornman PC, van Wyk MEC, Kaye P, Marks IN, Terblanche J (1997) Preliminary results of the proton-pump inhibitor pantoprazole in patients with Zollinger-Ellison syndrome. Gastroenterology 112: A37

    Google Scholar 

  40. Creutzfeldt W (1988) The achlorhydria-carcinoid sequence: role of gastrin. Digestion 39: 61–79

    PubMed  CAS  Google Scholar 

  41. Wormsley KG (1988) Is chronic long-term inhibition of gastric secretion really dangerous. Scand J Gastroenterol Suppl 146: 166–174

    Article  PubMed  CAS  Google Scholar 

  42. Arnold R (1994) Safety of proton pump inhibitors — an overview. Aliment Pharmacol Ther 8: 65–70

    PubMed  Google Scholar 

  43. Stewart CA, Termanini B, Sutliff VE, Serrano J, Yu F, Gibril F, Jensen RT (1998) Assessment of the risk of iron malabsorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther 12: 83–98

    Article  PubMed  CAS  Google Scholar 

  44. Termanini B, Gibril F, Sutliff VE III, Yu F, Venzon DJ, Jensen RT (1998) Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med 104: 422–430

    Article  PubMed  CAS  Google Scholar 

  45. Koop H (1992) Review article: metabolic consequences of long-term inhibition of acid secretion by omeprazole. Aliment Pharmacol Ther 6: 399–406

    Article  PubMed  CAS  Google Scholar 

  46. Koop H, Bachern MG (1992) Serum iron, ferritin and vitamin B12 during prolonged omeprazole therapy. J Clin Gastroenterol 14: 288–292

    Article  PubMed  CAS  Google Scholar 

  47. Dutta SK (1994) Editorial: vitamin B12 malabsorption and omeprazole therapy. J Am Coll Nutr 13: 544–545

    PubMed  CAS  Google Scholar 

  48. Ekman L, Hansson E, Havu N, Carlsson E, Lundberg C (1985) Toxicological studies on omeprazole. Scand J Gastroenterol 20 (Suppl 108): 53–69

    Article  Google Scholar 

  49. Marcuard SP, Albernaz L, Khazanie PG (1994) Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med 120: 211–215

    PubMed  CAS  Google Scholar 

  50. Havu N (1986) Enterochromaffin-like cell carcinoids of gastric mucosa in rats after lifelong inhibition of gastric secretion. Digestion 35 (Suppl 1): 42–55

    Article  PubMed  Google Scholar 

  51. Hakanson R, Ekelund M, Sundler F (1984) Activation and proliferation of gastric endocrine cells. In: S Falkmer, R Hakanson, F Sundler (eds): Evolution and tumor pathology of the neuroendocrine system. Elsevier, Amsterdam, 371–398

    Google Scholar 

  52. Helander HF, Bordi C (1995) Morphology of gastric mucosa during prolonged hyper-gastrinemia. In: Mignon, RT Jensen (eds): Endocrine tumors of the pancreas: recent advances in research and management. Series: Frontiers in Gastrointestinal Research. S. Karger, Basel, Switzerland, 372–384

    Google Scholar 

  53. Mattsson H, Havu N, Brautigam J, Carlsson K, Lundell L, Carlsson E (1991) Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffinlikecell carcinoids in the rat. Gastroenterology 100:311–319

    PubMed  CAS  Google Scholar 

  54. Havu N, Mattsson H, Ekman L, Carlsson E (1990) Enterochromaffin-like cell carcinoids in the rat gastric mucosa following long-term administration of ranitidine. Digestion 45: 189–195

    Article  PubMed  CAS  Google Scholar 

  55. Rindi G, Bordi C, Rappel S, La Rosa S, Stolte M, Solcia E (1996) Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 20: 168–172

    Article  PubMed  CAS  Google Scholar 

  56. D’Adda T, Corleto V, Pilato FP, Baggi MT, Robutti F, Delle Fave G, Bordi C (1990) Quantitative ultrastructure of endocrine cells of oxyntic mucosa in Zollinger-Ellison syndrome. Correspondence with light microscopic findings. Gastroenterology 99: 17–26

    PubMed  Google Scholar 

  57. Lehy T, Cadiot G, Mignon M, Ruszniewski P, Bonfils S (1992) Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome. Gut 33: 1275–1279

    Article  PubMed  CAS  Google Scholar 

  58. Jensen RT (1993) Gastrinoma as a model for prolonged hypergastrinemia in man. In: JH Walsh (ed): Gastrin. Raven Press, New York, 373–393

    Google Scholar 

  59. Cadiot G, Vissuzaine C, Potet F, Mignon M (1995) Fundic argyrophil carcinoid tumor in a patient with sporadic-type Zollinger-Ellison syndrome. Dig Dis Sci 40: 1275–1278

    Article  PubMed  CAS  Google Scholar 

  60. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA et al (1997) Positional cloning of the gene for multiple endocrine neoplasia-Type 1. Science 276: 404–407

    Article  PubMed  CAS  Google Scholar 

  61. Maton PN, Lack EE, Collen MJ? Cornelius MJ, David E, Gardner JD, Jensen RT (1990) The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells. Gastroenterology 99: 943–950

    PubMed  CAS  Google Scholar 

  62. Schenk BE, Festen HPM, Kuipers EJ, Klinkenberg-Knol EC, Meuwissen GM (1996) Effect of short-and long-term treatment with omeprazole on the absorption and serum levels of cobalamin. Aliment Pharmacol Ther 10: 541–545

    Article  PubMed  CAS  Google Scholar 

  63. Hakanson R, Sundler F (1986) Mechanisms for the development of gastric carcinoids. Digestion 35 (Suppl 1): 1–151

    Google Scholar 

  64. Lamberts R, Creutzfeldt W, Stockmann F, Jacubaschke U, Maas S, Brunner G (1988) Long-term omeprazole treatment in man: effects on gastric endocrine cell populations. Digestion 39: 126–135

    Article  PubMed  CAS  Google Scholar 

  65. Cook JD, Lipschitz DA, Miles LEM, Finch CA (1974) Serum ferritin as a measure of iron stores in normal subjects. Am J Clin Nutr 27: 681–687

    PubMed  CAS  Google Scholar 

  66. London J, Frucht H, Doppman JL, Maton PN, Gardner JD, Jensen RT (1989) Zollinger-Ellison syndrome in the acute care setting. J Intensive Care Med 4: 272–283

    Article  Google Scholar 

  67. Vinayek R, Frucht H, London JF, Miller LS, Stark HA, Norton JA, Cederberg C, Jensen RT, Gardner JD, Maton PN (1990) Intravenous omeprazole in patients with Zollinger-Ellison syndrome undergoing surgery. Gastroenterology 99: 10–16

    PubMed  CAS  Google Scholar 

  68. Vinayek R, Hahne WF, Euler AR, Norton JA, Jensen RT (1993) Parenteral control of gastric hypersecretion in patients with Zollinger-Ellison syndrome. Dig Dis Sci 38: 1857–1865

    Article  PubMed  CAS  Google Scholar 

  69. Saeed ZA, Norton JA, Frank WO, Young MD, Maton PN, Gardner JD, Jensen RT (1989) Parenteral antisecretory drug therapy in patients with Zollinger-Ellison syndrome. Gastroenterology 96: 1393–1402

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, 20892-1804, USA

    Robert T. Jensen

Authors
  1. Robert T. Jensen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Centre for Gastroenterological Research, University of Göteborg, S-41345, Göteborg, Sweden

    Lars Olbe

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Basel AG

About this chapter

Cite this chapter

Jensen, R.T. (1999). Zollinger-Ellison syndrome. In: Olbe, L. (eds) Proton Pump Inhibitors. Milestones in Drug Therapy MDT. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8795-3_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8795-3_13

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9777-8

  • Online ISBN: 978-3-0348-8795-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation